Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Stock Chart & Stats
$58.02
-$0.14(-8.75%)
At close: 4:00 PM EST
$58.02
-$0.14(-8.75%)
Day’s Range― - ―
52-Week Range$5.67 - $58.02
Previous CloseN/A
Volume421.15K
Average Volume (3M)4.84M
Market Cap
$1.61B
Enterprise Value$923.92M
Total Cash (Recent Filing)$157.34M
Total Debt (Recent Filing)$2.60M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,710,870
10 Day Avg. Volume2,254,318
30 Day Avg. Volume4,838,458
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.62K
Enterprise Value/Ebitda-8.55
Forecast
1Y Price Target
$58.00Price Target Upside-0.03% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-3.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPhase two head-to-head data in chronic spontaneous urticaria showed comparable or numerically better efficacy and a clean safety profile versus the established therapy, supporting progression to pivotal studies.
Commercial Potential And Strategic BackingGSK's acquisition of the asset combined with a large, underserved food allergy market creates a pathway for broad commercialization if pivotal trials confirm benefit.
Dosing Convenience And Patient EligibilityA longer half-life and stronger reduction of free IgE could enable less frequent injections and make treatment accessible to patients who are too heavy or have very high IgE levels for the incumbent therapy.
Bears Say
Analyst Sentiment And Market ReactionAn analyst downgrade linked to the acquisition highlights potential negative market perception and the risk of near-term selling pressure on the stock.
Deal Structure And Partner ObligationsThe transaction grants GSK rights outside certain Asian territories while triggering milestone and royalty payments to a partner, which could reduce net economics and complicate commercial returns.
Regulatory And Execution RiskAdvancement into pivotal testing depends on positive trial outcomes and regulatory alignment, creating execution and regulatory risk if studies do not meet expectations or agencies disagree with the development plan.
RAPT Therapeutics News
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $5.67 and its highest was $58.02 in the past 12 months.
What is RAPT Therapeutics’s market cap?
RAPT Therapeutics’s market cap is $1.61B.
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 60 days.
How were RAPT Therapeutics’s earnings last quarter?
Currently, no data Available
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Overvalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 27,710,870 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RAPT Therapeutics?
Currently, no hedge funds are holding shares in RAPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RAPT Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$58.00 (-0.03% Downside)
$58.00 (-0.03% Downside)
Blogger Sentiment
Bullish
RAPT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 642.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-85.37%
Trailing 12-Months
Asset Growth
52.80%
Trailing 12-Months
Company Description
RAPT Therapeutics
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Stock 12 Month Forecast
Average Price Target
$58.00
▼(-0.03% Downside)
Technical Analysis
Neurogene
―
DBV Technologies SA - American
―
Autolus Therapeutics
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
2.14% Insiders
4.37% Mutual Funds
16.20% Other Institutional Investors
69.71% Public Companies and
Individual Investors